





Serplulimab, an Anti-PD-1 Monoclonal Antibody for the Treatment of SCLC

A unique mode of recognition

The PD-1/PD-L1 Pathway Is an Important Regulator of the Immune System



- PD-1 is a co-inhibitory receptor expressed on the surface of activated T cells and other immune cells. Its ligands, PD-L1 and PD-L2, are mainly expressed on antigen-presenting cells and tumor cells
- The binding of PD-1 to its ligands regulates T-cell effector functions during various physiological responses—such as acute and chronic infection—and the maintenance of immune tolerance




Cancer cells use the PD-1/PD-L1 pathway to escape T-cell-mediated destruction.

- PD-L1 is highly expressed in a variety of cancers, including lung cancer
- Increased expression of PD-L1 in tumor tissues and on antigen-presenting cells in the tumor microenvironment results in T-cell immunosuppression, exhaustion of tumor-specific T cells, and cancer escape

Serplulimab: An Anti-Programmed Cell Death 1 (PD-1) mAb With a Favorable Binding Profile

- Novel fully humanized anti-PD-1 IgG4 mAb
- Activates T-cell proliferation and cytokine secretion in T-cells in in vivo studies
- Similar or better PD-L1 and PD-L2 blockade than a nivolumab analogue based on flow cytometry
- Similar antitumor activity compared with pembrolizumab based on in vivo mouse models
- Unique mode of recognition of the PD-1 receptor when comparing complex structure models with currently available anti-PD-1 mAbs

Comparison of Binding Epitope Regions (Blue) of Serplulimab With Pembrolizumab and Nivolumab



MOA is hypothesized and is not meant to imply clinical efficacy.

Serplulimab is not approved for use in the United States (US). Clinical investigation of serplulimab in the US is underway.

IgG4=human immunoglobulin G4; mAb=monoclonal antibody; PD-1=programmed death-1; PD-L1=programmed death ligand-1; PD-L2=programmed death ligand-2.


Issafras H, et al. *PLoS One*. 2021;16(12):e0257972.

Serplulimab Can Restore T-cell Immunity by Blocking the PD-1/PD-L1 Pathway¹

- Inhibition of the PD-1/PD-L1 pathway can enable tumor-reactive T cells to recognize tumor antigens and enhance the T-cell anti-tumor response¹

Serplulimab works synergistically with chemotherapy and/or radiation to enhance tumor-killing effects^{2,3}

- The cytotoxic effects of chemotherapy and/or radiation on tumor cells increase the release and presentation of tumor antigens to T cells²
- Inhibition of the PD-1/PD-L1 pathway and subsequent restoration of T-cell immunity with serplulimab may produce a stronger and more durable response against these tumor antigens¹





Serplulimab is not approved for use in the United States (US). Clinical investigation of serplulimab in the US is underway.

1. Issafras H, et al. *PLoS One*. 2021;16(12):e0257972. 2. Fabian KP, Wolfson B, Hodge JW. *Front Oncol*. 2021;11:728018. 3. Cheng Y, et al; ASTRUM-005 Study Group. *JAMA*. 2022;328(12):1223-1232.

Antitumor Activity With Serplulimab Showed a Pronounced Effect on Tumor Growth In Vivo

When compared with currently available anti-PD-1 antibodies in in vivo mouse models, serplulimab showed similar or better PD-L1 blockade and antitumor activity



* $P < 0.05$. ** $P < 0.001$. *** $P < 0.0001$.

Serplulimab is not approved for use in the United States (US). Clinical investigation of serplulimab in the US is underway.

mAb=monoclonal antibody; PD-1=programmed death-1; PD-L1=programmed death ligand-1; SEM=standard error of the mean.

Issafras H, et al. *PLoS One*. 2021;16(12):e0257972.

Global and US Development Pathway for Serplulimab

© 2024 Fosun Pharma USA, Inc. All rights reserved.
SER-MED-001-v2.0-08/2024

FOSUN PHARMA
USA INC.



Global Development Pathway for Serplulimab, an Anti-PD-1 Monoclonal Antibody for the Treatment of ES-SCLC




Serplulimab is not approved for use in the United States (US). Clinical investigation of serplulimab in the US is underway.

1L=first-line; EC=European Commission; EMA=European Medical Agency; ESCC=esophageal squamous cell carcinoma; ES-SCLC=extensive-stage small cell lung cancer; MSI-H=microsatellite instability-high; NMPA=National Medical Products Administration; PD-1=programmed death-1; PD-L1=programmed death ligand-1; SCLC=small cell lung cancer; sqNSCLC=squamous non-small cell lung cancer.

1. Press release. Shanghai Henlius Biotech, Inc. March 25, 2022. <https://www.henlius.com/en/NewsDetails-3512-26.html>
2. Press release. Shanghai Henlius Biotech, Inc. November 1, 2022. <https://www.henlius.com/en/NewsDetails-3837-26.html>
3. Press release. Shanghai Henlius Biotech, Inc. January 17, 2023. <https://www.henlius.com/en/NewsDetails-3949-26.html>
4. Press release. Shanghai Henlius Biotech, Inc. September 22, 2023. <https://www.henlius.com/en/NewsDetails-4283-26.html>
5. Press release. Shanghai Fosun Pharmaceutical Co., Ltd. December 15, 2022. https://www.fosunpharma.com/en/content/details38_12122.html
6. Press release. Shanghai Heliuss Biotech, Inc. March 23, 2023. <https://www.henlius.com/en/NewsDetails-4074-26.html>
7. Press release. Shanghai Henlius Biotech, Inc. September 21, 2024. <https://www.henlius.com/en/NewsDetails-4712-26.html>
8. Press release. Shanghai Henlius Biotech, Inc. February 5, 2025. <https://www.henlius.com/en/NewsDetails-4859-26.html>

Development Pathway for Serplulimab in the US



Serplulimab is not approved for use in the United States (US). Clinical investigation of serplulimab in the US is underway.

1L=first-line; ES-SCLC=extensive-stage small cell lung cancer; FDA=US Food and Drug Administration; LS-SCLC=limited-stage small cell lung cancer; NDA=new drug application; SCLC=small cell lung cancer.

1. Press release. Shanghai Henlius Biotech, Inc. April 7, 2022. <https://www.henlius.com/en/NewsDetails-3525-26.html> 2. Press release. Shanghai Henlius Biotech, Inc. September 28, 2022. <https://www.henlius.com/en/NewsDetails-3768-26.html> 3. Press release. Shanghai Henlius Biotech, Inc. November 29, 2022. <https://www.henlius.com/en/NewsDetails-3880-26.html> 4. Press release. Shanghai Henlius Biotech, Inc. January 5, 2023. <https://www.henlius.com/en/NewsDetails-3935-26.html> 5. ClinicalTrials.gov. NCT05353257. <https://classic.clinicaltrials.gov/ct2/show/NCT05353257> 6. ClinicalTrials.gov. NCT05468489. <https://classic.clinicaltrials.gov/ct2/show/NCT05468489>